Prognostic significance of neutrophil-to-lymphocyte ratio in non-small cell lung cancer: a meta-analysis

Xiao-Bin Gu; Tian Tian; Xiao-Jing Tian; XIAO-JUN ZHANG

doi:10.1038/srep12493

journal article Open Access Jul 24, 2015

Prognostic significance of neutrophil-to-lymphocyte ratio in non-small cell lung cancer: a meta-analysis

Xiao-Bin Gu Tian Tian

Xiao-Jing Tian XIAO-JUN ZHANG

Scientific Reports Vol. 5 No. 1 · Springer Science and Business Media LLC

View at Publisher Save 10.1038/srep12493

Abstract

AbstractPublished data on the prognostic significance of neutrophil-to-lymphocyte ratio (NLR) in non-small cell lung cancer (NSCLC) are controversial. We performed a meta-analysis to more accurately assess its prognostic value. The analysis was performed based on the data from 14 studies with 3,656 patients to estimate the correlation between NLR and overall survival (OS) and progression-free survival (PFS) in NSCLC. Hazard ratio (HR) with 95% confidence interval (CI) were calculated to estimate the effect. We also conducted subgroup analysis and meta-regression analysis. The results demonstrated that elevated pretreatment NLR predicted poorer OS (HR: 1.70, 95% CI: 1.39–2.09) and PFS (HR: 1.63, 95% CI: 1.27–2.09) in patients with NSCLC. Subgroup analysis indicated that cut-off value of 5 showed consistently prognostic value. There was no significant heterogeneity or publication bias for OS and PFS for included studies. This meta-analysis revealed that elevated pretreatment NLR might be a predicative factor of poor prognosis for NSCLC patients.

Topics

No keywords indexed for this article. Browse by subject →

References

42

[1]

Global cancer statistics

Ahmedin Jemal, Freddie Bray, Melissa M. Center et al.

CA: A Cancer Journal for Clinicians 2011 10.3322/caac.20107

[2]

Siegel, R. et al. Cancer treatment and survivorship statistics, 2012. CA-Cancer J. Clin. 62, 220–241, 10.3322/caac.21149 (2012). 10.3322/caac.21149

[3]

Paesmans, M. et al. Prognostic factors for survival in advanced non-small-cell lung cancer: univariate and multivariate analyses including recursive partitioning and amalgamation algorithms in 1,052 patients. The European Lung Cancer Working Party. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 13, 1221–1230 (1995). 10.1200/jco.1995.13.5.1221

[4]

Proctor, M. J. et al. The relationship between the presence and site of cancer, an inflammation-based prognostic score and biochemical parameters. Initial results of the Glasgow Inflammation Outcome Study. British journal of cancer 103, 870–876, 10.1038/sj.bjc.6605855 (2010). 10.1038/sj.bjc.6605855

[5]

Sieghart, W. et al. Single determination of C-reactive protein at the time of diagnosis predicts long-term outcome of patients with hepatocellular carcinoma. Hepatology 57, 2224–2234, 10.1002/hep.26057 (2013). 10.1002/hep.26057

[6]

Gomez, D., Morris-Stiff, G., Toogood, G. J., Lodge, J. P. & Prasad, K. R. Impact of systemic inflammation on outcome following resection for intrahepatic cholangiocarcinoma. J Surg Oncol 97, 513–518, 10.1002/jso.21001 (2008). 10.1002/jso.21001

[7]

Inflammation and cancer

Lisa M. Coussens, Zena Werb

Nature 2002 10.1038/nature01322

[8]

McMillan, D. C. The systemic inflammation-based Glasgow Prognostic Score: A decade of experience in patients with cancer. Cancer treatment reviews 39, 534–540, 10.1016/j.ctrv.2012.08.003 (2013). 10.1016/j.ctrv.2012.08.003

[9]

Sugiura, T., Uesaka, K., Kanemoto, H., Mizuno, T. & Okamura, Y. Elevated Preoperative Neutrophil-to-lymphocyte Ratio as a Predictor of Survival After Gastroenterostomy in Patients with Advanced Pancreatic Adenocarcinoma. Annals of surgical oncology 20, 4330–4337, 10.1245/s10434-013-3227-8 (2013). 10.1245/s10434-013-3227-8

[10]

De Larco, J. E., Wuertz, B. R. & Furcht, L. T. The potential role of neutrophils in promoting the metastatic phenotype of tumors releasing interleukin-8. Clinical cancer research : an official journal of the American Association for Cancer Research 10, 4895–4900, 10.1158/1078-0432.ccr-03-0760 (2004). 10.1158/1078-0432.ccr-03-0760

[11]

Kuang, D. M. et al. Peritumoral neutrophils link inflammatory response to disease progression by fostering angiogenesis in hepatocellular carcinoma. Journal of hepatology 54, 948–955, 10.1016/j.jhep.2010.08.041 (2011). 10.1016/j.jhep.2010.08.041

[12]

Sun, Z. & Yang, P. Role of imbalance between neutrophil elastase and alpha 1-antitrypsin in cancer development and progression. The Lancet. Oncology 5, 182–190, 10.1016/s1470-2045(04)01414-7 (2004). 10.1016/s1470-2045(04)01414-7

[13]

Horne, Z. D. et al. Increased levels of tumor-infiltrating lymphocytes are associated with improved recurrence-free survival in stage 1A non-small-cell lung cancer. The Journal of surgical research 171, 1–5, 10.1016/j.jss.2011.03.068 (2011). 10.1016/j.jss.2011.03.068

[14]

Krenn-Pilko, S. et al. The elevated preoperative platelet-to-lymphocyte ratio predicts poor prognosis in breast cancer patients. British journal of cancer 110, 2524–2530, 10.1038/bjc.2014.163 (2014). 10.1038/bjc.2014.163

[15]

Stotz, M. et al. The preoperative lymphocyte to monocyte ratio predicts clinical outcome in patients with stage III colon cancer. British journal of cancer 110, 435–440, 10.1038/bjc.2013.785 (2014). 10.1038/bjc.2013.785

[16]

Limaye, A. R. et al. Neutrophil-lymphocyte ratio predicts overall and recurrence-free survival after liver transplantation for hepatocellular carcinoma. Hepatology research : the official journal of the Japan Society of Hepatology 43, 757–764, 10.1111/hepr.12019 (2013). 10.1111/hepr.12019

[17]

Hu, K., Lou, L., Ye, J. & Zhang, S. Prognostic role of the neutrophil-lymphocyte ratio in renal cell carcinoma: a meta-analysis. BMJ open 5, e006404, 10.1136/bmjopen-2014-006404 (2015). 10.1136/bmjopen-2014-006404

[18]

Zhang, X., Zhang, W. & Feng, L. J. Prognostic significance of neutrophil lymphocyte ratio in patients with gastric cancer: a meta-analysis. PloS one 9, e111906, 10.1371/journal.pone.0111906 (2014). 10.1371/journal.pone.0111906

[19]

Unal, D., Eroglu, C., Kurtul, N., Oguz, A. & Tasdemir, A. Are Neutrophil/Lymphocyte and Platelet/Lymphocyte Rates in Patients with Non-Small Cell Lung Cancer Associated with Treatment Response and Prognosis? Asian Pac. J. Cancer Prev. 14, 5237–5242, 10.7314/apjcp.2013.14.9.5237 (2013). 10.7314/apjcp.2013.14.9.5237

[20]

Yao, Y. W., Yuan, D. M., Liu, H. B., Gu, X. L. & Song, Y. Pretreatment neutrophil to lymphocyte ratio is associated with response to therapy and prognosis of advanced non-small cell lung cancer patients treated with first-line platinum-based chemotherapy. Cancer Immunology Immunotherapy 62, 471–479, 10.1007/s00262-012-1347-9 (2013). 10.1007/s00262-012-1347-9

[21]

Cannon, N. A. et al. Neutrophil-lymphocyte and platelet-lymphocyte ratios as prognostic factors following stereotactic radiation therapy for early-stage non-small cell lung cancer. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 10.1097/jto.0000000000000399 (2014). 10.1016/j.ijrobp.2014.05.1851

[22]

Kacan, T. et al. Could the Neutrophil to Lymphocyte Ratio be a Poor Prognostic Factor for Non Small Cell Lung Cancers? Asian Pac. J. Cancer Prev. 15, 2089–2094, 10.7314/apjcp.2014.15.5.2089 (2014). 10.7314/apjcp.2014.15.5.2089

[23]

Pinato, D. J. et al. Prognostic performance of inflammation-based prognostic indices in primary operable non-small cell lung cancer. British journal of cancer, 10.1038/bjc.2014.145. (2014). 10.1038/bjc.2014.145

[24]

Lee, Y. et al. Early neutrophil-to-lymphocyte ratio reduction as a surrogate marker of prognosis in never smokers with advanced lung adenocarcinoma receiving gefitinib or standard chemotherapy as first-line therapy. Journal of cancer research and clinical oncology 138, 2009–2016 (2012). 10.1007/s00432-012-1281-4

[25]

Teramukai, S. et al. Pretreatment neutrophil count as an independent prognostic factor in advanced non-small-cell lung cancer: An analysis of Japan Multinational Trial Organisation LC00-03. European journal of cancer 45, 1950–1958, 10.1016/j.ejca.2009.01.023 (2009). 10.1016/j.ejca.2009.01.023

[26]

Tomita, M., Shimizu, T., Ayabe, T., Yonei, A. & Onitsuka, T. Preoperative neutrophil to lymphocyte ratio as a prognostic predictor after curative resection for non-small cell lung cancer. Anticancer research 31, 2995–2998 (2011).

[27]

Cedres, S. et al. Neutrophil to lymphocyte ratio (NLR) as an indicator of poor prognosis in stage IV non-small cell lung cancer. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 14, 864–869, 10.1007/s12094-012-0872-5 (2012). 10.1007/s12094-012-0872-5

[28]

Botta, C. et al. Systemic inlammatory status at baseline predicts bevacizumab beneit in advanced non-small cell lung cancer patients. Cancer Biology and Therapy 14, 469–475 (2013). 10.4161/cbt.24425

[29]

Forget, P. et al. Neutrophil:lymphocyte ratio and intraoperative use of ketorolac or diclofenac are prognostic factors in different cohorts of patients undergoing breast, lung and kidney cancer surgery. Annals of surgical oncology 20 Suppl 3, S650–660, 10.1245/s10434-013-3136-x (2013). 10.1245/s10434-013-3136-x

[30]

Jafri, S. H., Shi, R. & Mills, G. Advance lung cancer inflammation index (ALI) at diagnosis is a prognostic marker in patients with metastatic non-small cell lung cancer (NSCLC): A retrospective review. BMC cancer 13, 10.1186/1471-2407-13-158. (2013). 10.1186/1471-2407-13-158

[31]

Lin, G. N. et al. Elevated neutrophil-to-lymphocyte ratio predicts poor outcome in patients with advanced non-small-cell lung cancer receiving first-line gefitinib or erlotinib treatment. Asia Pac J Clin Oncol, 10.1111/ajco.12273 (2014). 10.1111/ajco.12273

[32]

Choi, J. E. et al. Perioperative neutrophil:lymphocyte ratio and postoperative NSAID use as predictors of survival after lung cancer surgery: a retrospective study. Cancer medicine, 10.1002/cam4.428 (2015). 10.1002/cam4.428

[33]

E, Y., He, N., Wang, Y. & Fan, H. Percutaneous transluminal angioplasty (PTA) alone versus PTA with balloon-expandable stent placement for short-segment femoropopliteal artery disease: a metaanalysis of randomized trials. Journal of vascular and interventional radiology : JVIR 19, 499–503, 10.1016/j.jvir.2007.12.446 (2008). 10.1016/j.jvir.2007.12.446

[34]

Hallmarks of Cancer: The Next Generation

Douglas Hanahan, Robert A. Weinberg

Cell 2011 10.1016/j.cell.2011.02.013

[35]

Mantovani, A., Allavena, P., Sica, A. & Balkwill, F. Cancer-related inflammation. Nature 454, 436–444, 10.1038/nature07205 (2008). 10.1038/nature07205

[36]

Pillay, J. et al. A subset of neutrophils in human systemic inflammation inhibits T cell responses through Mac-1. Journal of Clinical Investigation 122, 327–336, 10.1172/jci57990 (2012). 10.1172/jci57990

[37]

Motomura, T. et al. Neutrophil-lymphocyte ratio reflects hepatocellular carcinoma recurrence after liver transplantation via inflammatory microenvironment. Journal of hepatology 58, 58–64, 10.1016/j.jhep.2012.08.017 (2013). 10.1016/j.jhep.2012.08.017

[38]

Yang, X., Huang, Y., Feng, J. F. & Liu, J. S. Prognostic significance of neutrophil-to- lymphocyte ratio in esophageal cancer: a meta-analysis. OncoTargets and therapy 8, 789–794, 10.2147/ott.s77099 (2015). 10.2147/ott.s77099

[39]

Yang, J. J. et al. Prognostic significance of neutrophil to lymphocyte ratio in pancreatic cancer: a meta-analysis. World journal of gastroenterology : WJG 21, 2807–2815, 10.3748/wjg.v21.i9.2807 (2015). 10.3748/wjg.v21.i9.2807

[40]

Prognostic significance of neutrophil-lymphocyte ratio in hepatocellular carcinoma: a meta-analysis

Wei-Kai Xiao, Da Chen, Shao-Qiang Li et al.

BMC Cancer 10.1186/1471-2407-14-117

[41]

Li, M.-X. et al. Prognostic role of neutrophil- to- lymphocyte ratio in colorectal cancer: A systematic review and meta- analysis. International Journal of Cancer 134, 2403–2413, 10.1002/ijc.28536 (2014). 10.1002/ijc.28536

[42]

Practical methods for incorporating summary time-to-event data into meta-analysis

Jayne F Tierney, Lesley A Stewart, Davina Ghersi et al.

Trials 2007 10.1186/1745-6215-8-16

Cited By

168

Stratified impact analysis of intrinsic phenotypes and therapeutic interventions on the clinical prognosis of cross-disease validation: right treatment for right patient in precision radiotherapy

Qijian Lu, Shutong Yu · 2026

Applied Radiation and Isotopes

A Novel Paradigm Between Leukocytosis, G-CSF Secretion, Neutrophil-to-Lymphocyte Ratio, Myeloid-Derived Suppressor Cells, and Prognosis in Non-small Cell Lung Cancer

Montreh Tavakkoli, Cy R. Wilkins · 2019

Frontiers in Oncology

Prognostic value of platelet to lymphocyte ratio in non-small cell lung cancer: evidence from 3,430 patients

Xiaobin Gu, Shaoqian Sun · 2016

Scientific Reports

Prognostic significance of neutrophil-to-lymphocyte ratio in prostate cancer: evidence from 16,266 patients

Xiaobin Gu, Xianshu Gao · 2016

Scientific Reports

Metrics

168

Citations

42

References

Details

Published: Jul 24, 2015
Vol/Issue: 5(1)
License: View

Authors

Cite This Article

Xiao-Bin Gu, Tian Tian, Xiao-Jing Tian, et al. (2015). Prognostic significance of neutrophil-to-lymphocyte ratio in non-small cell lung cancer: a meta-analysis. Scientific Reports, 5(1). https://doi.org/10.1038/srep12493

Prognostic significance of neutrophil-to-lymphocyte ratio in non-small cell lung cancer: a meta-analysis

You May Also Like